Clay Thorp - Profile and Investment Details

Investor Profile

Clay Thorp is a Venture Capital, Investor, Private Equity Firm based in Chapel Hill, North Carolina, United States with a diverse investment portfolio that includes companies such as Standard Bariatrics, Contego Medical, Clearside Biomedical, Vigil Neuroscience, Artizan Biosciences, MATI Energy, SpineAlign Medical, Lysosomal Therapeutics, Kymera Therapeutics, Spyryx Biosciences, Bivarus, AtaCor Medical, Pathfinder Therapeutics, Jumo Health, Clinipace, StrideBio, GrayBug, Nusirt, WalletFi, Ribometrix, Curoverse, Rodin Therapeutics, Medfusion, GeneCentric Diagnostics, Boragen, Myeloid Therapeutics, Trefoil Therapeutics, Empliant, G1 Therapeutics, ArtusLabs, Clinverse, Elligo Health Research, Atsena Therapeutics, PhaseBio Pharmaceuticals, HistoSonics, Boston Immune Technologies & Therapeutics, NeuroTronik, Altis Biosystems, Viamet Pharmaceuticals, Coferon, TetraLogic Pharmaceuticals, ORIG3N, 410 Medical, CVRx, Qpex Biopharma, Qvella Corporation, NurseGrid, Sideris Pharmaceuticals, Wildflower Health, Shattuck Labs. Over time, Clay Thorp has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Clay Thorp is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Medical Testing, Android, Life Science, Information Technology (IT), Biotech, Medical Device, Software, Diagnostics, Healthcare, Biotechnology, Health Diagnostics, Medical, Therapeutics, Media and Entertainment, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Clay Thorp, as their portfolio suggests a familiarity and interest in this area.

Understanding Clay Thorp’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.